|Previous Section||Index||Home Page|
29 Mar 2004 : Column 1226Wcontinued
The NSF for coronary heart disease already has a reduction in cigarette smoking as one of its major targets. We have also banned tobacco advertising and made smoking reduction aids available on national health service prescription.
Additionally the National Institute for Clinical Excellence issued clinical guidelines for the NHS on 27 February 2004 for the prevention, diagnosis, management and treatment of chronic obstructive pulmonary disease.
Ms Rosie Winterton: The Medicines and Healthcare products Regulatory Agency (MHRA) and the Committee on Safety of Medicines (CSM) receive reports of suspected adverse drug reactions (ADRs) submitted by health professionals on a voluntary basis via the yellow card scheme and there is a legal requirement for companies to report suspected ADRs to their drugs.
Mr Hunter: To ask the Secretary of State for Health (1) if he will take measures to ensure that all surviving UK recipients of the St. Jude silzone heart valve are informed why these valves have been withdrawn from the market; and if he will make a statement; 
Miss Melanie Johnson: The Department issued advice to United Kingdom cardiothoracic surgeons and cardiologists on the problems associated with the St. Jude Silzone heart valve in November 1999 and January 2000. Specifically, the Department advised clinicians of the recall of Silzone heart valves of the increased risk of complications with the Silzone heart valves and of the consequent need to undertake early
29 Mar 2004 : Column 1227W
review of all patients implanted with these valves. Clinicians are responsible for acting on this advice and for bringing relevant information to the attention of their patients.
Mr. Hunter: To ask the Secretary of State for Health what communication his Department has had with relevant authorities in the Irish Republic regarding the implications for British and Irish citizens of the withdrawal from the market of the St Jude silzone heart valve; and if he will make a statement. 
Miss Melanie Johnson: The Department notified other European competent authorities of the action taken in the United Kingdom, in relation to Silzone heart valves, via notifications through the Medical Devices Vigilance System on 19 November 1999 and 3 February 2000. These notifications informed other competent authorities of the UK's recommendation to undertake an early review of all patients implanted with the Silzone heart valve and gave background to this
29 Mar 2004 : Column 1228W
Miss Melanie Johnson [holding answer 22 March 2004]: There are 475 alcohol treatment centres in England. We estimate that around £95 million is spent each year on alcohol treatment services in England. Most of the funding for alcohol treatment services is drawn from the mainstream budgets of the national health service and local authorities. The method of funding these services means that it is not possible to give a breakdown at regional level of budgets and expenditure.
29 Mar 2004 : Column 1229W
John McDonnell: To ask the Chancellor of the Exchequer how many (a) births and (b) birth defects there were in the London borough of Hillingdon in each year since 1994; and what the rate of birth defects per 10,000 births was in the borough in each of those years. 
|Total live and stillbirths||Estimated number of malformations notified||Rates per 10,000 live and stillbirths|
(34) Notification to this system is voluntary at all stages and therefore may be incomplete, particularly in areas that are not covered by a local registry.
(35) Figures provided are by year of birth.
(36) In 2000, NCAS began exchanging data with the North Thames (West) Congenital Malformation Register, which receives more complete information through multi-source ascertainment. It is a hospital-based register and includes information supplied from the maternity unit in Hillingdon. It is likely that the inclusion of data from this register contributed to the large increase in the estimated number of malformations in Hillingdon in 2000.
Estimates based on numbers of babies notified to National Congenital Anomaly System at 31 July 2002 (Health Statistics Quarterly no. 16 Annual update: Congenital anomaly statisticsnotifications 2001) and the number of malformations recorded for each notified case.
29 Mar 2004 : Column 1230W
(37) International Classification of Diseases, Tenth Revision (ICD-10) code C00-C97 excluding non-melanoma skin cancerICD-10 code C44.
Office for National Statistics.
(38) Mid-year estimates of population.
Office for National Statistics.
29 Mar 2004 : Column 1231W
29 Mar 2004 : Column 1232W
|England and Wales||7,440||7,504||8,220||10,168||10,874||9,423|
|Government Office Regions|
|Yorkshire and the Humber||858||913||740||1,103||1,186||973|
(39) Notification to this system is voluntary at all stages and therefore coverage may be incomplete, particularly in areas that are not covered by a local registry. From 1998, ONS began to exchange data with local registers and by 2001, four such registers were exchanging data with NCAS. As a result, the total coverage of NCAS has increased.
(40) Figures provided are by year of birth.
Estimates based on numbers of babies notified to National Congenital Anomaly System (NCAS) at 31 July 2002 (Health Statistics Quarterly no. 16 Annual update: Congenital anomaly statisticsnotifications 2001) and the number of malformations recorded for each notified case.
|Next Section||Index||Home Page|